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To the Editor:
Cardiac troponin is the standard
biomarker for detection of myocar-
dial injury. An increase of cardiac
troponin99th percentile by use of
a sufficiently sensitive and precise as-
say is required to diagnose acute
myocardial infarction (MI)1 and is
increasingly measured by use of
high-sensitivity cardiac troponin T
(hs-cTnT) and hs-cTnI assays out-
side the US. In patients with stable
coronary artery disease (SCAD), hs-
cTnT can be detected in 80% of
patients (1 ), with values above the
99th percentile in approximately
11% of patients (2 ). Increasing con-
centrations of hs-cTnT and hs-cTnI
above the 99th percentile are also as-
sociated with an increased risk of ad-
verse cardiovascular events (2, 3 ).
The mechanisms underlying cardiac
troponin increase remain unclear,
but may include silent plaque rup-
ture, inducible ischemia, anatomic
burden of CAD, cardiac structural
abnormalities, or impaired left ven-
tricular (LV) function (4, 5 ).
We evaluated serial changes in
hs-cTnT (Elecsys 2010, Roche Di-
agnostics, detection limit 3 ng/L,
10% CV 13.5 ng/L, 99th percentile
value of 14 ng/L) (6 ), sensitive
cTnI, (S-cTnI) (TnI Ultra, Advia
Centaur, Siemens Healthcare Diag-
nostics, detection limit 0.006 g/L,
10% CV 0.045 g/L, level 2 assay)
(7, 8 ), heart fatty acid binding pro-
tein (HFABP) (Evidence Investigator,
Randox Laboratories, 99th percentile
5.8 g/L, CV 5%) (9), and N-
terminal pro-B-type natriuretic pep-
tide (NT-pro-BNP) (Elecsys 2010,
RocheDiagnostics, CV 3.2%–2.4%
175–4962 ng/L with an analytic
range 5–35000 ng/L) (10 ) in outpa-
tients referred for exercise echocar-
diography with suspected angina
pectoris and normal resting LV
function (ejection fraction 50%)
without overt cardiac structural ab-
normality. Blood was sampled be-
fore, immediately after, and 3 h after
symptom-limited Bruce treadmill
exercise testing. hs-cTnT, S-cTnI,
NT-pro-BNP, and HFABP were
analyzed with previously reported
age- and sex-specific 99th percentile
(8, 9, 11 ) and cutoff (10 ) values.
LV dimensions, systolic function, is-
chemic burden, exercise duration,
and myocardial workload were cal-
culated from the exercise echocar-
diograms. All biomarker and echo-
cardiographic analyses were blinded.
Categorical data were com-
pared with 2, McNemar, or Fisher
exact test. Numerical data were
compared with the Wilcoxon rank-
sum test (for median and interquar-
tile range) or 2-sample t-test (for
mean and SD). P  0.05 was con-
sidered significant, after Bonferroni
correction for multiple compari-
sons, where applicable.
In 45 patients (mean age 60.2
years, SD 12.3, 71% male, 47%
known CAD, 22% diabetic), hs-
cTnT increased significantly imme-
diately (P  0.0001) and 3 h (P 
0.0001) postexercise compared with
baseline and was above the 99th per-
centile in 4%, 18%, and 18%of par-
ticipants at baseline, immediately
postexercise, and after 3 h (P 
0.03). There was a significant in-
crease in hs-cTnT from immediately
to 3 h postexercise (P  0.023).
There was a 20.1% increase in geo-
metric mean of S-cTnI values at
3 h postexercise (P  0.06), which
were above the 99th percentile in
75% of those individuals with hs-
cTnT 99th percentile. NT-pro-
BNP was increased in 71%, 78%,
and 76% of participants at baseline
and immediately and 3 h postexer-
cise, respectively. NT-pro-BNP at
3 h postexercise was significantly as-
sociated with total exercise time
(P  0.002). HFABP did not in-
crease with exercise (Fig. 1).
In the subset of patients in
whom hs-cTnT was above the 99th
percentile at 3 h postexercise (n 
11), (a) hs-cTnT was 8.8 (1.5, 20.4)
ng/L at baseline, 41.1 (8.5, 30.5)
ng/L immediately postexercise, and
90.3 (59.0, 115.6) ng/L at 3 h
postexercise (P  0.0001 vs base-
line); (b) S-cTnI was 0.009 (0.009,
0.013) g/L at baseline, 0.022
(0.009, 0.031) g/L immediately
postexercise, and 0.066 (0.033,
0.083)g/L at 3 h postexercise (P
0.001 vs baseline); (c) NT-pro-BNP
was 122 (105.5, 168) ng/L at base-
line, 126 (99, 245.5) ng/L immedi-
ately postexercise, and 133.5 (110,
281) ng/L at 3 h postexercise (P 
0.65 vs baseline); and (d) HFABP
was 2.9 (2.7, 3.2) g/L at baseline,
3.5 (2.5, 4.6) g/L immediately
postexercise, and 3.3 (2.7, 5.8)g/L
at 3 h postexercise (P  0.30 vs
baseline).
Participants with hs-cTnT
above the 99th percentile at 3 h had
lower body mass index (P  0.006)
and exercised for longer (616 vs
458 s, P  0.02) but achieved a
similar peak workload [assessed by
rate–pressure product (RPP) 24827
(5635) mmHg/min] compared with
those with hs-cTnT 99th percen-
tile [RPP 24691 (6033) mmHg/
min] (P  0.95). The association
with diabetes mellitus was P  0.08,
and there was no significant associa-
tionbetween3-hhs-cTnTandhistory
of CAD (P  0.44), Seattle Angina
Questionnaire (P 0.86), and echo-
1 Nonstandard abbreviations: MI, myocardial infarction;
hs-cTnT, high-sensitivity cardiac troponin T; hs-cTnI,
high-sensitivity cardiac troponin I; SCAD, stable coro-
nary artery disease; S-cTnI, sensitive cardiac troponin I;
HFABP, heart fatty acid binding protein; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; LV, left ven-
tricular; RPP, rate–pressure product.
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cardiographic parameters of LV size,
function, or reversible ischemia.
The main findings (Fig. 1) of
this preliminary study were (a) hs-
cTnT increased immediately after
modest treadmill exercise and rose
above the 99th percentile; (b) longer
exercise duration was significantly as-
sociated with 3-h postexercise hs-
cTnT (P 0.02), S-cTnI (P 0.01),
and NT-pro-BNP (P  0.002) in-
crease, despite no significant differ-
ence in maximum achieved myocar-
dial workload as assessed by RPP; (c)
in 70% of participants, NT-pro-
BNP was increased despite normal
echocardiograms, with a trend to in-
crease with exercise; and (d) exercise-
induced hs-cTnT increase was not as-
sociated with detectable reversible
ischemia or increased HFABP.
Our findings are consistent
with previous reports of measurable
cTn concentrations in patients with
SCAD (1–3 ). Although it is known
that hs-cTnT can increase after ex-
treme exercise proportionately to ex-
ercise duration and intensity, in the
current study hs-cTnT increased
immediately after a brief episode of
modest exercise. S-cTnI was above
the 99th percentile in 75% of pa-
tients, with hs-cTnT above the 99th
percentile at 3 h. The differences in
hs-cTnT and S-cTnI results postex-
ercise may be explained by differ-
ences in assay sensitivity and level of
detection. We observed no relation-
ship between either baseline or 3-h
hs-cTnT or S-cTnI and inducible
myocardial ischemia. The time
course and absence of associated LV
impairment at peak stress without
increase of HFABP suggest the pos-
sibility of noninjury or nonischemic
cardiac troponin release. Increasing
NT-pro-BNP likely reflects the neu-
rohormonal response to the hemo-
dynamic stress of exercise.
Our observations may be rele-
vant when acutely evaluating pa-
tients with early testing protocols
that use high-sensitivity cardiac tro-
ponin assays, many of whom have
low pretest probabilities for acute
MI. Further adequately powered
studies to confirm these preliminary
findings and investigate potential
determinants, mechanisms, and di-
agnostic and prognostic significance
of baseline and exercise-induced car-
diac troponin, NT-pro-BNP, and
HFABP release in patients with
known or suspected SCAD are
warranted.
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Fig. 1. Change in hs-cTnT (ng/L), NT-pro-BNP (ng/L), and HFABP (μg/L) at baseline, immediately postexercise, and 3 h postexercise
in patients with hs-cTnT above the 99th percentile at 3 h postexercise (n = 45).
Data are median and interquartile range. *P< 0.0001 vs baseline; †P= 0.0001 vs baseline.
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